Phase 3, Multi-center, Single-arm, Open-label Study Evaluating The Efficacy, Safety, And Pharmacokinetics Of Da-9501 (Dexmedetomidine Hydrochloride) In Pediatric Subjects In The Intensive Care Unit
Phase of Trial: Phase III
Latest Information Update: 13 Jun 2017
At a glance
- Drugs Dexmedetomidine (Primary)
- Indications Sedation
- Focus Therapeutic Use
- Sponsors Pfizer
- 08 Jun 2017 Status changed from recruiting to completed.
- 14 Feb 2017 Planned End Date changed from 1 May 2017 to 1 Sep 2017.
- 14 Feb 2017 Planned primary completion date changed from 1 May 2017 to 1 Sep 2017.